Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Avastin Bevacizumab Platinum Resistant Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Kyprolis (with lenalidomide) Carfilzomib (with lenalidomide) Multiple Myeloma Reimburse with clinical criteria and/or conditions Complete
Zepatier Elbasvir/grazoprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Fycompa Perampanel Epilepsy, primary generalized tonic-clonic seizures Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic non small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Blincyto Blinatumomab Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete
Jakavi Ruxolitinib Polycythemia vera Reimburse with clinical criteria and/or conditions Complete
Praluent Alirocumab Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete
Imbruvica Ibrutinib Mantle Cell Lymphoma (relapsed/refractory) Reimburse with clinical criteria and/or conditions Complete
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) Reimburse with clinical criteria and/or conditions Complete